Background: Asthma is an allergic airway disease (AAD) caused by aberrant immune
hyper-responsiveness (AHR). 2, 3 Together, these events drive the development and progression of allergic asthma. 2 The chronic release of cytokines and remodelling factors such as transforming growth factor (TGF)-b by eosinophils and Th2 cells damages the epithelial lining and leads to airway remodelling. 4 Current mainstay asthma therapies include corticosteroids and long-acting b-agonists.
These reduce symptoms but do not treat the underlying causes of the disease, and their use has numerous issues. 2 There is an urgent need for effective alternative treatments.
PP2A is the most abundant serine/threonine phosphatase, is expressed ubiquitously and exists as a heterotrimeric enzyme consisting of structural (A), regulatory (multiple) (B) and catalytic (C) subunits. 5, 6 Reduced PP2A activity occurs in animal models of AAD and patients with severe asthma, [7] [8] [9] and enhancing activity with fingolimod (FTY720) or 2-amino-4-(4-(heptyloxy) phenyl)-2-methylbutan-1-ol (AAL (S) ) inhibited the development of inflammation and AHR in AAD as well as inhibited IL-6 secretion in corticosteroidinsensitive A549 lung epithelial cells. 7, 10, 11 While these studies suggest that these agents may be potential asthma therapies, it is unknown which is more effective, as a side-by-side comparison has not been made.
The ubiquitin proteasome system (UPS) is critical in regulating tissue homeostasis through the degradation of key proteins involved in cellular functions. 12, 13 Ubiquitinated target proteins are selectively degraded by ubiquitin ligases. In the lungs, the ubiquitin E3 ligase, Itch, promotes immune tolerance by degrading the Th2-specific transcription factor, phosphorylated JunB. 14 In murine AAD, Itch deficiency resulted in allergic inflammation in response to high-dose antigen. 15 Another E3 ligase, Midline-1 (MID1), is upregulated in human primary bronchial epithelial cells (pBECs) upon house dust mite (HDM) and rhinovirus exposure and in HDM-induced AAD. 7 The proteasome inhibitor, bortezomib (BORT), is approved for the treatment of multiple malignancies. 16 Its protective effects are due in part to the suppression of nuclear factor kappa light chain enhancer of activated B cells (NF-jB) signalling, which leads to the downregulation of antiapoptotic target genes. 17 Thus, BORT may suppress airway inflammation driven by NF-jB, which indicates the potential for targeting the UPS by proteasome inhibition as a therapy for asthma.
Comparing and combining drugs that increase PP2A activity and suppress proteasome activity and the determination of any synergistic effects have not been assessed in asthma. Here, we demonstrate that increasing PP2A activity with AAL (S) Figure 1A) . Vehicle or the PP2A activators FTY720 or AAL (S) were administered i.p 30 minutes before each challenge. AAD was associated with increases in total leucocytes, eosinophils, neutrophils, 
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We assessed the effects of enhancing PP2A activity and inhibiting PP2A is the most abundant serine/threonine phosphatase in mammals, 6 and numerous studies show that its activity is reduced in asthma. 9, [28] [29] [30] PP2A activity was impaired in airway smooth muscle cells of asthmatics compared to nonasthmatics, 28 in peripheral blood In contrast to our findings, others showed that oral treatment with FTY720 decreased airway inflammation, MSC numbers and AHR in T-cell transfer-and OVA-induced AAD. 31 This was postulated to be due to the sequestration of T cells in lymphoid tissues.
Another study showed that intratracheal administration of FTY720 during OVA-induced AAD reduced airway inflammation and type 2 cytokines (IL-5, IL-13) by altering the function of lung dendritic cells. 10 The differences in our compared to other studies could be partly due to the off-target effects of FTY720, different routes of administration or mouse strains used. As FTY720 is phosphorylated in vivo by sphingosine kinases to become FTY720-P and also binds to sphingosine 1-phosphate receptors (SIPR1) to cause lymphocyte trafficking, it does not specifically activate PP2A. 32 In contrast, AAL (S) does not bind to SIPR1, and more specifically increases PP2A activity. In our study, FTY720 was administered systemically (i.p) compared to oral or intratracheal administration used by others, which may have resulted in greater metabolism to FTY720-P. Furthermore, others used BALB/c mice that are more susceptible to developing Th2-driven AAD, while we used C57BL/6 mice that can be considered to have more balanced immunity. By using C57BL/6 mice that are less susceptible to developing AAD, our data add additional impact and demonstrate that the protective effects of targeting these pathways are not restricted only to susceptible strains. It also provides a platform for further mechanistic studies using factordeficient or transgenic mice that are typically generated on a C57BL/6 background (eg in mice with altered tristetraprolin (TTP) TTP activity). 33 The effects of AAL (S) on airway remodelling were also determined, and treatment suppressed chronic HDM-induced collagen deposition around the airways. This was associated with reduced TGF-b mRNA expression in the lungs. Others also showed that AAL (S) treatment reduced collagen deposition around the airways of mice chronically exposed to OVA. 34 Our study used HDM, which is a clinically relevant allergen, and involves sensitization solely via the airways instead of systemic sensitization in the presence of an adjuvant used in OVA models. 35 This is consistent with allergen exposure in humans and results in local, instead of systemic immune responses.
The UPS has been studied extensively; however, few have focussed on asthma. 7, 36 In the lungs, the E3 ubiquitin ligase, Itch, is involved in maintaining tolerance by inducing anergy in Th2 cells. 15 Other E3 ubiquitin ligases such as gene related to anergy in lymphocytes (GRAIL) are implicated in inducing T-cell tolerance by targeting Th2 transcription factors for degradation. 36 Recently, MID1 was shown to be upregulated in pBECs from human asthma patients and in HDM-exposed mice. 7 Proteasome inhibition is emerging as a potential therapy in many diseases particularly cancer, whereas studies in asthma are only commencing. Treatment with the inhibitor PS-519 in OVA-induced pulmonary eosinophilia in rats significantly reduced eosinophil influx into the lungs. 37 Only one other study used BORT, which was tested in a chronic OVA mouse model. Longterm treatment with high doses reduced OVA-specific IgE, but not airway inflammation or AHR. 38 However, the effects of treatment in acute models, with HDM or on features of airway remodelling have not been assessed previously.
We assessed the effects of BORT on both acute and chronic models of AAD. Treatment suppressed some features of acute AAD, including eosinophil infiltration into the airways and lung tissue, which was associated with reduced levels of IL-5 and IL-13 in BAL supernatants. It also attenuated AHR, which was consistent with reduced levels of IL-13. However, treatment did not alter tissue inflammation, MSC numbers, levels of innate type 2 cytokines (IL-33
and TSLP) or IgE. Importantly, it did prevent airway remodelling in chronic AAD, which was associated with reduced TGF-b mRNA expression in the lung. Discrepancies between our and previous findings may be attributed to the doses of BORT used. 38 We used a moderate dose (0.2 mg/kg), while a higher dose of BORT Several studies highlight associations between PP2A and the UPS. Inhibition of PP2A augmented the proteolytic function of murine cardiac proteasomes. 40 Others identified the mediation of PP2A/ C ubiquitination and degradation by the E3 ligase Cullin-3, 41 and in HDM-induced AAD, MID1 protein decreases PP2A activity. 7 Given that both PP2A and the UPS are implicated in asthma pathogenesis and that AAL (S) and BORT inhibit different features of AAD, the complementary effects of enhancing PP2A activity and inhibiting proteasome activity concurrently were determined. This has not been assessed previously. Treatment with AAL (S) +BORT had complementary effects and suppressed the major hallmark features of AAD including eosinophil infiltration into the airways and lungs, tissue inflammation, MSC numbers, type 2-associated cytokines, AHR and collagen deposition. Notably, type 2 cytokine production and AHR were completely inhibited. Interestingly, combined treatment reduced the levels of eosinophils in the airways, which was not observed with AAL (S) treatment alone. This is important because anti-IL-5 treatment in humans is only effective when there is major suppression of eosinophil levels. 42, 43 The effects of combined treatment were stronger in the acute compared to the chronic model. In All BALF cells
-represents no effect; ↓ represents reduced; ↓↓ represents reduced to baseline, BALF, bronchoalveolar lavage fluid; MSCs, mucus-secreting cells; Muc5AC. mucin 5AC; IL, interleukin; TSLP, thymic stromal lymphopoietin; Ig, immunoglobulin; AHR, airway hyper-responsiveness; BORT, bortezomib. The exact mechanisms of how these immunomodulatory drugs suppress AAD remain to be fully elucidated. A recent study showed that PP2A activators may promote increases in antiinflammatory TTP activity. 30 The TTP protein exists in two forms, the phosphorylated form, which is inactive, and the unphosphorylated form, which is active and induces mRNA decay.
The major targets of TTP are the mRNA transcripts of cytokines.
Thus, when TTP is phosphorylated, cytokine expression occurs, but when TTP is unphosphorylated, the production of target cytokines is inhibited. Unphosphorylated TTP is less stable and is degraded by the UPS. 44, 45 PP2A is able to mediate the dephosphorylation of TTP protein, leading to an increase in the active unphosphorylated form and the mRNA decay of cytokines. 46 Inhibition of PP2A with okadaic acid or siRNA leads to increased phosphorylation of TTP, thereby increasing the stability of increased TTP protein levels by preventing its degradation. 44 These findings suggest that enhancing PP2A activity and inhibiting proteasome activity, as we have done in this study, could potentially increase the active and stable form of TTP, hence leading to reduced levels of pro-inflammatory cytokines and the suppression of AAD.
Another possible mechanism is through the inhibition of NF-jB activity, which regulates the expression of many cytokines. 48 PP2A
is a crucial regulator of NF-jB. 49 Its inhibition increases the activity of inhibitor of jB (IjB) kinaseb (IKKb), which subsequently leads to the proteasomal degradation of IjBa, allowing NF-jB to translocate into the nucleus to activate responsive genes. 49 The UPS also controls NF-jB activity through IjB degradation. 50 The inhibition of tumour growth in human T-cell lymphoma cells by BORT may be | 1901 due to nuclear translocation of IjB and the inactivation of NFjB. 51 The mechanisms of action of these drugs clearly need further study.
While we did not directly confirm the activity of the drugs (AAL (S) and BORT) against their targets (PP2A and UPS) at the doses provided, several studies have confirmed this. PP2A activity was shown to be increased in mice with AAD after treatment with AAL (S). 7 BORT is a known proteasome inhibitor that has been approved for use in multiple myeloma, and it inhibits proteasomal activity by up to 70% in whole blood samples. 52 Similarly, proteasome activity was inhibited both in vitro and in vivo. 53, 54 Notably, the doses used in these studies were lower than the dose used in our study, indicating that we would also observe the desired effects on the target pathways. Importantly, we did not observe any adverse effects on the mice at the doses used in our study.
In summary, we demonstrate that enhancing PP2A activity and inhibiting proteasome activity, either alone or in combination, have 
